Patients with JIA-associated uveitis often relapse after stopping immunomodulatory therapy

MAR 29, 2018

Uveitis


This retrospective study assessed outcomes and relapse rates among patients with juvenile idiopathic arthritis (JIA)-associated uveitis upon discontinuation of immunomodulatory therapy (IMT).

Study design

The authors identified medical records from 66 patients with JIA-associated uveitis who were treated at 2 institutions. The main outcome was time to relapse after starting IMT taper or stopping IMT.

Outcomes

Of 66 patients, 51 patients (77%) received corticosteroid-sparing IMT, either with a single agent or as combination therapy. The most common medications used were methotrexate (86%), followed by adalimumab (25%) and infliximab (24%). Seven patients were also on oral prednisone; 35 patients were on topical steroids.

During follow-up, 19 of 51 patients (37%) attempted IMT discontinuation. Approximately 68% relapsed at a median time of 288 days. Of note, 9 of 11 patients on TNF-alpha inhibitors relapsed after the medication was stopped.

The time to relapse was longer in patients who had remission as reason for discontinuation of medication compared with those who stopped therapy for reasons other than remission.

Limitations

The study was limited by its small sample size and retrospective nature. The study was also underpowered to determine significant predictors of relapse. Reasons for IMT withdrawal were not listed. Various tapering strategies of the doctors included in the study.

Clinical significance

In patients on IMT for JIA-associated uveitis, the discontinuation of IMT, especially TNF-alpha inhibitors, was often unsuccessful. Physicians should closely monitor patients after discontinuation of therapy.

View Abstract Ocular Immunology and Inflammation, February 2018

https://www.lvcenter4sight.com/patients-with-jia-associated-uveitis-often-relapse-after-stopping-immunomodulatory-therapy/

Comments

Post a Comment

Popular posts from this blog

Week in review: Pay raise, Von’s Vision, gonio-<em>what?</em>

Image
APR 13, 2018 By Anni Griswold Comprehensive Ophthalmology, Cornea/External Disease, Glaucoma, Pediatric Ophth/Strabismus Above: The GonioPEN (Credit: Nanyang Technological University) A weekly roundup of ophthalmic news from around the web. Ophthalmologists earn more than the average physician , and their salaries are on the rise (+3% over the last year, to be precise). Eye docs will earn a mean $375,000 this year—more than the physician average of $299,000, but well below a typical plastic surgeon’s paycheck. See for yourself in Medscape’s 2018 Physician Compensation Report . Medscape A special supplement to USA Today will highlight the work of Von Miller , a 28-year-old linebacker for the Denver Broncos and former Super Bowl MVP. Through his foundation, Von’s Vision, Miller connects thousands of underprivileged children in Denver with affordable, high-quality eye care. His interview will appear in the “Vision Health” campaign during World Glaucoma Week, available in pr...
Read more

Patch with Microneedles Could Replace Eye Injections

Image
Instead of getting eye injections, patients with serious eye diseases may be eligible for a contact lens-type patch. 1 Injections are often recommended for eye diseases such as Wet (advanced) Age-Related Macular Degeneration, macular edema, and glaucoma. The new patch is inserted painlessly like a contact lens. It delivers tiny microneedles containing medication. The microneedles are made from natural materials and dissolve over time, gradually releasing medicine. Patients would be more likely to stick with a regimen that does not involve eye injections. Eye Injections: Stick a Needle in My Eye Patients generally dread eye injections. Injections must be performed in a doctor’s office. Eye injections can be painful, and they are inconvenient. They can introduce infection. And they can damage the eye. Avastin, Eylea, and Lucentis are injectable medications that discourage new blood vessel growth. These anti-VEGF medicines are useful for advanced Macular Degeneration , Diabetic Retino...
Read more

Incidence of eyelid SCC appears to be rising

FEB 12, 2018 Oculoplastics/Orbit This retrospective study examined demographic risk factors for developing eyelid squamous cell carcinoma (SCC). Study design Using data from the National Cancer Registration and Analysis Service, investigators identified all cases of eyelid SCC in England between 2000 and 2014. Outcomes Over the 15-year study period, there were 4,022 patients with newly diagnosed SCC affecting the eyelid. The age-standardized number of reported cases of eyelid SCC rose approximately 2% per year over the study period. The risk for developing an eyelid SCC approximately doubled each decade after age 60. Men were at 1.9-times greater relative risk compared with women. The authors did not find any association between income quintile and risk of SCC. Limitations The cause for the increasing incidence of eyelid SCC was not studied. While age may represent one factor, others such as an increasing rate of patients receiving immunosuppression therapies may als...
Read more